The data shown below were compiled from readership statistics for 29 Mendeley readers of this research output. Click here to see the associated Mendeley record.
| Title |
Considering renal risk while managing cancer
|
|---|---|
| Published in |
Cancer Management and Research, May 2017
|
| DOI | 10.2147/cmar.s125864 |
| Pubmed ID | |
| Authors |
Vahakn B Shahinian, Amit Bahl, Daniela Niepel, Vito Lorusso |
| Abstract |
Renal function is an important consideration in the management of patients with advanced cancer. There is a reciprocal relationship between cancer and the kidney: chronic kidney disease can increase the risk of developing cancer, and patients with cancer often experience renal impairment owing to age, disease-related factors and nephrotoxic treatments. As therapies for cancer continue to improve, patients are living longer with their disease, potentially extending the period over which they are susceptible to long-term complications. Furthermore, secondary symptoms, such as bone metastases or infections, may arise that will require treatment. Certain treatments, including chemotherapy, antibiotics and some bone-targeted agents, are nephrotoxic and may require dose modifications or interruptions to prevent renal injury. Nephrologists should play a key role in the identification and management of renal impairment in patients with cancer. Furthermore, they may be able to provide advice on protecting the kidneys in instances where nephrotoxic agents require dose reductions or interruptions, and when novel therapies or combinations are used. Collaboration between oncologists and nephrologists is important to optimal patient management. This article reviews the relationship between cancer and kidney disease and examines the treatments that may impact kidney function. Considerations for monitoring renal function are also discussed. |
Mendeley readers
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 29 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 5 | 17% |
| Student > Master | 4 | 14% |
| Student > Postgraduate | 3 | 10% |
| Student > Bachelor | 2 | 7% |
| Other | 2 | 7% |
| Other | 4 | 14% |
| Unknown | 9 | 31% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 9 | 31% |
| Biochemistry, Genetics and Molecular Biology | 3 | 10% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 10% |
| Psychology | 2 | 7% |
| Nursing and Health Professions | 1 | 3% |
| Other | 0 | 0% |
| Unknown | 11 | 38% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 17 June 2020.
All research outputs
#20,462,806
of 23,020,670 outputs
Outputs from Cancer Management and Research
#1,404
of 2,016 outputs
Outputs of similar age
#270,535
of 310,839 outputs
Outputs of similar age from Cancer Management and Research
#10
of 11 outputs
Altmetric has tracked 23,020,670 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,016 research outputs from this source. They receive a mean Attention Score of 3.0. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 310,839 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 11 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.